Middle East and Africa In-Vitro Diagnostics Market Size (2024 - 2029)

The Middle East and Africa In-Vitro Diagnostics market is projected to experience growth over the forecast period, driven by the high prevalence of chronic diseases such as infectious diseases, diabetes, and cancers in the region. The COVID-19 pandemic significantly boosted the market due to increased demand for diagnostic kits and reagents, although a post-pandemic decline in demand is anticipated as vaccination rates rise and infection rates fall. Despite these growth drivers, the market's expansion may be hindered by stringent regulatory requirements.

Market Size of Middle East and Africa In-Vitro Diagnostics Industry

Middle East and Africa In-Vitro Diagnostics Market  Summary
Study Period 2021 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Market Size (2024) USD 4.52 Billion
Market Size (2029) USD 5.76 Billion
CAGR (2024 - 2029) 4.95 %

Major Players

Middle East and Africa In-Vitro Diagnostics Market  Major Players

*Disclaimer: Major Players sorted in no particular order

Middle East and Africa In-Vitro Diagnosis & Treatment Market Analysis

The Middle East and Africa In-Vitro Diagnostics Market size is estimated at USD 4.52 billion in 2024, and is expected to reach USD 5.76 billion by 2029, growing at a CAGR of 4.95% during the forecast period (2024-2029).

The COVID-19 pandemic had a significant impact on the in-vitro diagnostics market since there was an increasing demand for IVD kits and reagents for the rapid and accurate diagnosis of SARS-CoV-2 virus infection among the regional population. As per the 2022 report from the United Nations, with the help of several initiatives, including the establishment of the Regional Centre of Excellence for Genomic Surveillance and Bioinformatics in South Africa in collaboration with the SANBI at the University of Western Cape, the WHO increased the number of laboratories able to detect COVID-19 from two to more than 900. WHO also supported genetic sequencing efforts in Africa. In comparison to a year ago, these efforts resulted in more than 7,500 samples in the southern African region, and the amount of sequencing data on the continent increased by more than 54%. The efforts implemented by the government and related resources stimulated the market growth for in-vitro diagnostics in the studied region amid the pandemic. However, as per the analysis, the demand for IVD products may observe a slight decline post pandemic phase owing to a reduction in the number of infected patients and a surge in the vaccination rate across the region.

The major driving factor linked to the growth of the IVD industry in the region is the high burden of chronic diseases, especially infectious diseases, diabetes, and cancers. The Middle East and Africa region is majorly affected due to the burden of chronic diseases. As per the 2021 report from the International Diabetes Federation (IDF), 24 million adults (20-79) are living with diabetes in the IDF Africa Region. This number is estimated to increase to 33 million by 2030 and 55 million by 2045. As per the same source, 73 million adults (20-79) were living with diabetes in the IDF Middle East and North Africa region in 2021. This number is estimated to increase to 95 million by 2030 and 136 million by 2045. The prime factor responsible for this rising burden is the lack of a proper healthcare system across African countries and low awareness about novel disease diagnosis techniques. As per the 2022 review report from UNAIDS, law reform in Angola enabled the country to make use of funds from the Global Fund to combat AIDS, tuberculosis, and malaria to reach young members of critical populations by making it easier for more young people to obtain HIV testing services.

Thus, due to this rise in chronic diseases, the Middle East & Africa In-Vitro Diagnostics market is expected to witness growth over the analysis period. However, stringent regulations associated with the products may restrain the market's growth.

Middle East and Africa In-Vitro Diagnosis & Treatment Industry Segmentation

As per the scope of the report, in-vitro diagnostics is defined as a medical device used alone or in combination, intended by the manufacturer for the in vitro examination of specimens derived from the human body solely or principally to provide information for diagnostic, monitoring, or compatibility purposes. The Middle East & Africa In-Vitro Diagnostics Market is segmented by Technique (Histochemistry, Molecular Diagnostics, Hematology, Self-blood Glucose Testing, Immunochemistry, and Other Techniques), Product (Instrument, Reagent, and Other Products), Usability (Disposable IVD Device, Reusable IVD Device), Application (Infectious Disease, Diabetes, Cancer/Oncology, Cardiology, Autoimmune Disease, and Other Applications) End User (Diagnostic Laboratories, Hospitals and Clinics, and Other End Users) Diagnostic Approach (Point-of-Care Diagnostics and Centralized Laboratory-based Diagnostics) and Geography (GCC, South Africa, Rest of Middle East & Africa). The report offers the value (in USD million) for the above segments.

By Technique
Histochemistry
Molecular Diagnostics
Hematology
Self-blood Glucose Testing
Immunochemistry
Other Techniques
By Product
Instrument
Reagent
Other Products
By Usability
Disposable IVD Device
Reusable IVD Device
By Application
Infectious Disease
Diabetes
Cancer/Oncology
Cardiology
Autoimmune Disease
Other Applications
By End User
Diagnostic Laboratories
Hospitals and Clinics
Other End Users (Academic and Medical School)
By Diagnostic Approach
Point-of-Care Diagnostics
Centralized Laboratory-based Diagnostics
Geography
GCC
South Africa
Rest of Middle East & Africa
Need A Different Region Or Segment?
Customize Now

Middle East and Africa In-Vitro Diagnostics Market Size Summary

The Middle East and Africa In-Vitro Diagnostics market is poised for growth, driven by the increasing prevalence of chronic diseases such as diabetes, infectious diseases, and cancers. The region has been significantly impacted by the COVID-19 pandemic, which heightened the demand for diagnostic kits and reagents, thereby stimulating market expansion. Initiatives like the establishment of the Regional Centre of Excellence for Genomic Surveillance in South Africa, supported by the WHO, have enhanced the region's diagnostic capabilities. However, the post-pandemic phase may see a slight decline in demand due to reduced infection rates and increased vaccination coverage. Despite this, the ongoing burden of chronic diseases, coupled with advancements in diagnostic technologies, is expected to sustain market growth. The diabetes segment, in particular, is anticipated to experience robust expansion due to the rising incidence of the disease and the implementation of medical management technologies across the region.

The GCC region is expected to witness significant growth in the in-vitro diagnostics market, fueled by increased healthcare expenditure and the high prevalence of chronic conditions like diabetes. Government initiatives, such as Saudi Arabia's substantial financial contributions to global health efforts during the pandemic, have further bolstered market development. The pandemic also underscored the importance of diagnostics, as evidenced by the high comorbidity rates of diabetes among COVID-19 patients. Strategic partnerships and investments in healthcare infrastructure, such as the joint venture between TIBBIYAH and Unilabs Diagnostics AB, are set to enhance diagnostic capabilities. The competitive landscape is dominated by major players like Abbott Laboratories, BioMerieux SA, and Sysmex Corporation, who are expanding their presence through strategic partnerships and product innovations. These factors collectively indicate a positive growth trajectory for the in-vitro diagnostics market in the Middle East and Africa over the forecast period.

Explore More

Middle East and Africa In-Vitro Diagnostics Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Growing Burden of Chronic Diseases

      2. 1.2.2 Increasing Use of Point-of-Care (PoC) Diagnostics

      3. 1.2.3 Increasing Use of Advanced Technologies

    3. 1.3 Market Restraints

      1. 1.3.1 Stringent Regulations

    4. 1.4 Porter's Five Force Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 2.1 By Technique

      1. 2.1.1 Histochemistry

      2. 2.1.2 Molecular Diagnostics

      3. 2.1.3 Hematology

      4. 2.1.4 Self-blood Glucose Testing

      5. 2.1.5 Immunochemistry

      6. 2.1.6 Other Techniques

    2. 2.2 By Product

      1. 2.2.1 Instrument

      2. 2.2.2 Reagent

      3. 2.2.3 Other Products

    3. 2.3 By Usability

      1. 2.3.1 Disposable IVD Device

      2. 2.3.2 Reusable IVD Device

    4. 2.4 By Application

      1. 2.4.1 Infectious Disease

      2. 2.4.2 Diabetes

      3. 2.4.3 Cancer/Oncology

      4. 2.4.4 Cardiology

      5. 2.4.5 Autoimmune Disease

      6. 2.4.6 Other Applications

    5. 2.5 By End User

      1. 2.5.1 Diagnostic Laboratories

      2. 2.5.2 Hospitals and Clinics

      3. 2.5.3 Other End Users (Academic and Medical School)

    6. 2.6 By Diagnostic Approach

      1. 2.6.1 Point-of-Care Diagnostics

      2. 2.6.2 Centralized Laboratory-based Diagnostics

    7. 2.7 Geography

      1. 2.7.1 GCC

      2. 2.7.2 South Africa

      3. 2.7.3 Rest of Middle East & Africa

Middle East and Africa In-Vitro Diagnostics Market Size FAQs

The Middle East and Africa In-Vitro Diagnostics Market size is expected to reach USD 4.52 billion in 2024 and grow at a CAGR of 4.95% to reach USD 5.76 billion by 2029.

In 2024, the Middle East and Africa In-Vitro Diagnostics Market size is expected to reach USD 4.52 billion.

Middle East and Africa In-Vitro Diagnosis & Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)